Sinusitis Treatment Market Size, Growth Analysis to 2027
The global Sinusitis Treatment market gathered revenue around USD 2.7 Billion in 2020 and market is set to grow USD 3.1 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 3.6% during the prediction period 2021 to 2027.
Report Coverage
| Report Scope | Details |
| Market Size | USD 3.1 Billion by 2027 |
| Growth Rate | CAGR of 3.6% From 2021 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2021 to 2027 |
| Historic Data | 2017 to 2020 |
| Report coverage | Growth Factors, Revenue Status, Competitive Landscape, and Future Trends |
| Segments Covered | Treatment, Disease Type, Route of Administration, Distribution Channel and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co, Inc. |
Growth Factors:
Sinuses are a connected system of air-filled cavities located in the skull. Sinusitis is an inflammation of the sinus lining caused by bacteria, virus, fungi, or microbes. Bacterial sinusitis is less common than viral sinusitis and requires antibiotics, while viral sinusitis is most common and does not require antibiotics. Fungal sinusitis is also known as allergic fungal sinusitis, and caused by the aspergillosis fungi. Possible symptoms of sinus infections are nasal obstruction, discolored nasal discharge, and facial pain that lasts for seven days or more. Facial pain is a common symptom in sinusitis. A patient could feel pain around the eye, forehead, nose, and root of teeth.
The three primary types of sinusitis are acute sinusitis, sub-acute sinusitis, and chronic sinusitis. Acute sinusitis is also known as acute bacterial rhinosinusitis, and it lasts less than 30 days, while chronic sinusitis lasts more than three months. Sinusitis infection can be diagnosed through physical examination of color and characteristics of nasal mucosa, presence of polyps, and structure of nasal septum. Imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound can also be used for the diagnosis of sinus infections.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Sinusitis Treatment market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Sinusitis Treatment market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Sinusitis Treatment market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Asia Pacific to Lead Sinusitis Treatment Market
In terms of region, the global sinusitis treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a significant share of the global market because of higher prevalence of sinusitis. According to the Centers for Disease Control and Prevention (CDC), nearly 26.9 million people were diagnosed with sinusitis in the U.S. in 2019. Europe is anticipated to be a key market for sinusitis treatment due to rise in invasive bacterial diseases and innovation in diagnosis of bacterial infections. The sinusitis treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to increase in bacterial and viral diseases. However, factors, such as lack of knowledge of diagnostic tests and awareness among people about sinusitis is likely to hamper the growth of the market in the region.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Sinusitis Treatment Market are: Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Global Sinusitis Treatment Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Sinusitis Treatment Market, By Treatment
7.1. Sinusitis Treatment Market, by Treatment, 2021-2027
7.1.1. Antihistamines
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Analgesics
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Corticosteroids
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Antibiotics
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. Sulphonamides
7.1.5.1. Market Revenue and Forecast (2016-2027)
7.1.6. Quinolones
7.1.6.1. Market Revenue and Forecast (2016-2027)
7.1.7. Surgery
7.1.7.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Sinusitis Treatment Market, By Disease Type
8.1. Sinusitis Treatment Market, by Disease Type, 2021-2027
8.1.1. Acute Sinusitis
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Sub-acute Sinusitis
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Chronic Sinusitis
8.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Sinusitis Treatment Market, By Route of Administration
9.1. Sinusitis Treatment Market, by Route of Administration, 2021-2027
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Nasal
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Oral
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Injectable
9.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Sinusitis Treatment Market, By Distribution Channel
10.1. Sinusitis Treatment Market, by Distribution Channel, 2021-2027
10.1.1. Online Pharmacies
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Hospital Pharmacies
10.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 11.Global Sinusitis Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.1.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.1.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.1.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.1.5.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.1.5.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.1.6.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.1.6.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.1.6.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.2.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.2.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.2.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.2.5.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.2.5.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Treatment(2016-2027)
11.2.6.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.2.6.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.2.7.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.2.7.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.2.8.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.2.8.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.2.8.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.3.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.3.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.3.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.3.5.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.3.5.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.3.6.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.3.6.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.3.7.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.3.7.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.3.8.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.3.8.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.3.8.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.4.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.4.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.4.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.4.5.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.4.5.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.4.6.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.4.6.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.4.7.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.4.7.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.4.8.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.4.8.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.4.8.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.5.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.5.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.5.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.5.5.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.5.5.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Treatment (2016-2027)
11.5.6.2. Market Revenue and Forecast, by Disease Type (2016-2027)
11.5.6.3. Market Revenue and Forecast, by Route of Administration (2016-2027)
11.5.6.4. Market Revenue and Forecast, by Distribution Channel (2016-2027)
Chapter 12. Company Profiles
12.1. Sun Pharmaceutical Industries, Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Janssen Pharmaceuticals, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Fresenius Kabi USA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. LLC
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Dr. Reddy's Laboratories, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Teva Pharmaceutical Industries Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abbott Laboratories
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers